Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Future Oncol
; 18(3): 277-289, 2022 Jan.
Article
em En
| MEDLINE
| ID: mdl-34854741
Lay abstract Idecabtagene vicleucel (ide-cel) is a novel therapy using a patient's own T cells that have been genetically modified to force them to recognize a target antigen called BCMA that is present on myeloma and plasma cells but not on other normal cells. This therapy, known as CAR T-cell therapy, has recently gained approval by the US FDA for relapsed multiple myeloma after clinical trials have demonstrated unprecedented results in this difficult-to-treat subgroup of patients who have failed at least four prior lines of therapy. As the first CAR T-cell product approved for myeloma, ide-cel is poised to become a practice-changing treatment option. This first-in-class therapeutic offers hope for more durable remissions, as well as a longer and better quality of life, following a single infusion. This paper reviews the ide-cel product in terms of design, pharmacology, efficacy and toxicity as described in studies reported to date.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imunoterapia Adotiva
/
Antineoplásicos Imunológicos
/
Receptores de Antígenos Quiméricos
/
Mieloma Múltiplo
/
Recidiva Local de Neoplasia
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos